<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
    March 22, 2022

    Arum Therapeutics Implements CDD Vault to Streamline Its Research Data and Collaboration Workflows

    CDD Press Release Logo

    SEOUL, South Korea and BURLINGAME, Calif. - March 22, 2022 - Arum Therapeutics Inc. (Arum), a leading pharmaceutical company that specializes in the discovery of new molecules and molecule combinations to target novel oncology announced today that it had implemented CDD Vault, a research data management platform developed by Collaborative Drug Discovery, Inc. (CDD), in its laboratories in Gangseo-gu, Seoul.

    Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers. The company exploits the concept of synthetic lethality targeting DNA Damage Response (DDR) pathways with the aim of blocking the cancer cell's primary and backup repair mechanisms, thus making it unable to survive. Additional pipelines in oncotargets complement the company's robust pipeline in this area.

    "At Arum, we are focused on treating cancers where conventional therapies are no longer effective. We have a unique approach that requires effective and secure data management and found that CDD Vault fulfils those requirements. We can easily access and navigate data in an intuitive way which allows us to be more productive", said Taegon Baik, CEO at Arum Therapeutics, "We fully expect the platform to grow with us as we expand the company and move our pipeline downstream."

    Arum's research data is stored, managed, and analysed in CDD Vault, a hosted informatics platform designed to handle drug discovery data and facilitate secure collaborations. The versatility of CDD Vault allows Arum to organise chemical, biological, and even mixture entities, as well as associated experiment protocols and results.

    "We are delighted to see Arum make use of CDD Vault's unique capabilities to gain insights from multiple data types and collaborate across disciplines," said Barry Bunin, CEO of CDD, "It is a true pleasure to support Arum's growth and expansion. Their novel approach to target drug-resistant cancer brings hope to millions of patients around the world."

    About Arum Therapeutics Inc.

    Arum Therapeutics (https://arumtherapeutics.com) is a leading pharmaceutical company that has strength in medicinal chemistry based on synthetic small molecules. The company develops novel anticancer agents to overcome current drug resistance using a platform for synthetic lethality (SL) target associated with the DNA damage response (DDR) mechanisms. The company is based in Seoul, South Korea.

    About Collaborative Drug Discovery, Inc.

    CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

    A complete list of more than 60 publications and patents from CDD can be found online on our resources page at https://www.collaborativedrug.com/publications-and-resources/.

    CDD Vault Logo CDD Vault Logo


    Media Contact: Barry Bunin, Ph.D., Collaborative Drug Discovery, marketing@collaborativedrug.com.

    Tag(s): CDD Blog , News

    Other posts you might be interested in

    View All Posts
    CDD Blog
    2 min   April 22, 2024
    Recorded Presentations: CDD 20th Anniversary User Group Meeting
    Read More
    CDD Blog
    9 min   April 19, 2024
    Drug Discovery Industry Roundup with Barry Bunin — April 19, 2024
    Read More
    CDD Blog
    2 min   April 19, 2024
    CDD Appoints Yasushi Hamagashira as Head of Sales and Marketing for Japan
    Read More